Loading...
Loading...
CING| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 3,282.1M |
| Gross Profit | -3,282.1M |
| Operating Expense | 3.3M |
| Operating I/L | -6,564.2M |
| Other Income/Expense | 3,332.6M |
| Interest Income | 0.0M |
| Pretax | -3,231.6M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -3,231.6M |
Cingulate Inc. is a clinical-stage biopharmaceutical company specializing in the development of product candidates for attention-deficit/hyperactivity disorder (ADHD) treatment. The company's lead product candidates, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), are in advanced stages of clinical trials for ADHD treatment. Additionally, the company is working on CTx-2103 for anxiety disorders. Cingulate Inc. generates revenue through the development and potential commercialization of these pharmaceutical products aimed at addressing unmet medical needs in the ADHD and anxiety disorder markets.
